Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Dec 5, 2025, 4:00 PM EST
2.040
-0.010 (-0.49%)
After-hours: Dec 5, 2025, 7:53 PM EST
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
$65,449
Profits / Employee
-$1,888,731
Market Cap
91.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OTLK News
- 11 days ago - Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 22 days ago - Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewsWire
- 3 months ago - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewsWire
- 3 months ago - Outlook Therapeutics Requests Type A Meeting with FDA - GlobeNewsWire
- 3 months ago - Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug - Invezz
- 3 months ago - FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Benzinga